An additional $884 million in funding has been allocated to buy more ingredients an antigen and an adjuvant for swine flu vaccines. This is in addition to the $1 billion The Department of Health and Human Services committed to fighting the Swine Flu in May.
San Diego-based Vical, a firm who is developing an H1N1 vaccine under an agreement with the U.S. Navy saw company shares climb 45 cents, to $2.65 on positive clinical trial news this week. Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Vical’s stock shot up 20 percent on the news that their swine flu jab sailed through an animal study with positive results. Vical’s H1N1 vaccine is now ready for a human study — marching into the clinic in record time.
Since 2004, HHS has contracted with manufacturers that currently hold U.S. licenses for flu vaccine as part of the National Strategy for Pandemic Influenza. In May 2009, HHS issued new orders on these contracts to produce a bulk supply of vaccine antigen and adjuvant and to produce pilot (also called investigational) lots of a 2009 H1N1 vaccine.
© 2002- An Inconvenient Woman. Site design and construction by Pleiades Publishing Services, Co.
Powered by Wordpress and based on the template design MyJournal Hypereal by 
BlogoSquare
